HC Wainwright & Co. Reiterates Buy on EyePoint Pharmaceuticals, Maintains $27 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on EyePoint Pharmaceuticals (NASDAQ:EYPT) and maintained a $27 price target.
June 06, 2023 | 10:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Yi Chen reiterates a Buy rating on EyePoint Pharmaceuticals and maintains a $27 price target.
The reiteration of the Buy rating and maintenance of the $27 price target by HC Wainwright & Co. analyst Yi Chen indicates a positive outlook for EyePoint Pharmaceuticals. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100